Use of angiogenesis inhibitors in tumour treatment
Open Access
- 31 May 2005
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 41 (8) , 1109-1116
- https://doi.org/10.1016/j.ejca.2005.02.017
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- ThalidomideThe Lancet, 2004
- Progress in the clinical development of new marine-derived anticancer compoundsAnti-Cancer Drugs, 2004
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I StudiesJournal of Clinical Oncology, 2003
- Celecoxib, a Selective Cyclo-Oxygenase-2 Inhibitor, Enhances the Response to Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumoursEuropean Journal Of Cancer, 2003
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Tumor Regression by Targeted Gene Delivery to the NeovasculatureScience, 2002
- VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude miceCancer Gene Therapy, 2002
- Host cyclooxygenase-2 modulates carcinoma growthJournal of Clinical Investigation, 2000